- BiondVax Pharmaceuticals Ltd. (BVXV): Important & Key Factors of Healthcare Stock
- What's the Analyst Recommendation for iHeartMedia Inc. (IHRT)?
- Let’s Take a Look at Milestone Pharmaceuticals Inc. (MIST) Stock
- Is it Time to Sell/Buy United States Steel Corporation (X) Stock After Recent Trade?
- Aptose Biosciences Inc. (APTO) is down -10.05% this year
Anavex Life Sciences Corp. (AVXL) share price soared 9.45% with the closing price of $4.75 on Thursday. Anavex Life Sciences Corp. stock has an exchanging volume of 11.95 million shares, which is high, contrasted with its 3-months average volume of 623.01K shares. Its market capitalization has now reached to $287.85M.
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia on October 15, 2020 news published at Yahoo.
Anavex Life Sciences Corp. (AVXL) declared results from the proof of concept Phase 2 controlled trial evaluating the safety, tolerability, and efficacy of ANAVEX®2-73 (blarcamesine) in patients with Parkinson’s disease dementia (PDD).
The study found that ANAVEX®2-73 (blarcamesine) was safe and well tolerated in oral doses up to 50 mg once daily. The results show clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. The study confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker of response to ANAVEX®2-73 (blarcamesine).
The ANAVEX®2-73-PDD-001 study was an international, double-blind, multicenter, placebo-controlled Phase 2 clinical study and randomized 132 patients with PDD equally to target doses of 30mg, 50mg ANAVEX®2-73 (blarcamesine) or placebo, respectively. In addition to safety and cognitive efficacy, sleep function was assessed during the study at week 8 and week 14.
ANAVEX®2-73-PDD-001 study results will be submitted for presentation at a medical conference and for publication in a peer-reviewed medical journal. Anavex is planning a pivotal trial of ANAVEX®2-73 (blarcamesine) in Parkinson’s disease dementia after submitting the results of the study to the FDA to obtain regulatory guidance.
After completing the trial, participants were able to enroll in a voluntary 48-week open-label extension study, ANAVEX®2-73-PDD-EP-001, which continues to assess safety, long term efficacy and changes in gut microbiota.
ANAVEX®2-73 (blarcamesine) is an orally available, small-molecule activator of the sigma-1 receptor, which has been shown to be pivotal to restoring neural cell homeostasis and promoting neuroplasticity.
Ladenburg Thalmann announced it was Initiated coverage of Anavex Life Sciences Corp. in a research note on September 28, 2020. Cantor Fitzgerald rated the stock as an Overweight in a research noted published on February 27, 2020. Janney rated the stock as a Buy in a research note published on June 18, 2019.
AVXL Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, AVXL price has rose by 9.70%. In the course of past three months sees the stock go up around 7.22%, while it has gain 47.06% over the past six months and 83.40% since the start of the year.
AVXL Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), Anavex Life Sciences Corp. posted -$0.11 earnings per share (EPS) which was above the consensus estimate of -$0.14 by $0.03, which represents to an expansion by 21.40%.
AVXL Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Anavex Life Sciences Corp. has seen its stock exchanging -15.03% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +29.98% above its three-month low. A more extensive look sees AVXL exchanging -24.72% beneath its 52-week high and 115.91% above from its 52-week low price.
AVXL Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 8.35%, while it has a month to month instability of 7.62%. The company has an ATR (Average True Range) of 0.34 and a beta factor of 1.04.